Cite
HARVARD Citation
Leppä, S. et al. (n.d.). YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDING BCL‐2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE‐DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS. Hematological oncology. p. 132. [Online].